tbuckley/cabot-search huggingface dataset:
Study Inclusions in the Association Between Screen Time and Neurodevelopment in Early Childhood—Reply
Authors: Kenji J. Tsuchiya, Yusuke Okubo, Tomoko Nishimura
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Study Inclusions in the Association Between Screen Time and Neurodevelopment in Early Childhood
Authors: Motoi Miura, Tetsuya Tanimoto
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Authors: Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Øivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trněný, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven, Pamela McCombe, Olga Skibina, Jeannette Lechner-Scott, Barbara Willekens, Elisabetta Cartechini, Serkan Ozakbas, Raed Alroughani, Jens Kuhle, Francesco Patti, Pierre Duquette, Alessandra Lugaresi, Samia J. Khoury, Mark Slee, Recai Turkoglu, Suzanne Hodgkinson, Nevin John, Davide Maimone, Maria Jose Sa, Vincent van Pesch, Oliver Gerlach, Guy Laureys, Liesbeth Van Hijfte, Rana Karabudak, Daniele Spitaleri, Tunde Csepany, Riadh Gouider, Tamara Castillo-Triviño, Bruce Taylor, Basil Sharrack, John A. Snowden, Dana Horakova, Katherine Buzzard, Murat Terzi, Alexandre Prat, Marc Girard, Pierre Grammond, Michael Barnett, Grace Stewart, Marco Onofrj, Guillermo Izquierdo, Sara Eichau, Francois Grand'Maison, Julie Prevost, Bart Van Wijmeersch, Maria Pia Amato, Vahid Shaygannejad, Cavit Boz, Ricardo Fernandez Bolaños, Aysun Soysal, Cristina Ramo-Tello, Claudio Solaro, Claudio Gobbi, Jose Antonio Cabrera-Gomez, Etienne Roullet, Cees Zwanikken, Leontien Den braber-Moerland, Norma Deri, Maria Laura Saladino, Edgardo Cristiano, Juan Ignacio Rojas, Carlos Vrech, Cameron Shaw, Neil Shuey, Mike Boggild, Ik Lin Tan, Todd Hardy, Danny Decoo, Fraser Moore, Jiwon Oh, Patrice Lalive, Radek Ampapa, Thor Petersen, Celia Oreja-Guevara, Angel Perez Sempere, Jose Andres Dominguez, Sarah Besora, Stella Hughes, Orla Gray, Nikolaos Grigoriadis, Imre Piroska, Csilla Rozsa, Krisztian Kasa, Magdolna Simo, Krisztina Kovacs, Attila Sas, Eniko Dobos, Cecilia Rajda, Chris McGuigan, Deborah Mason, Jan Schepel, Jabir Alkhaboori, Maria Edite Rio, Simu Mihaela, Talal Al-Harbi, Ayse Altintas, Ilya Kister, Mark Marriott, Trevor Kilpatrick, John King, Ai-Lan Nguyen, Chris Dwyer, Mastura Monif, Izanne Roos, Lisa Taylor, Matteo Diamanti, Clara Chisari, Simona Toscano, Lo Fermo Salvatore, Catherine Larochelle, Giovanna De Luca, Valeria Di Tommaso, Daniela Travaglini, Erika Pietrolongo, Maria di Ioia, Deborah Farina, Luca Mancinelli, Raymond Hupperts, Javier Olascoaga, Albert Saiz, Robert Zivadinov, Ralph Benedict, Freek Verheul, Marzena Fabis-Pedrini, Saloua Mrabet, Justin Garber, Jose Luis Sanchez-Menoyo, Eduardo Aguera-Morales, Yolanda Blanco, Abdullah Al-Asmi, Bianca Weinstock-Guttman, Yara Fragoso, Koen de Gans, Allan Kermode
Journal: JAMA Neurology (2023)

Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).
A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma
Authors: Stephen C. Mack, Kelsey C. Bertrand
Journal: Clinical Cancer Research (2023)

Glioblastoma (GBM) is a heterogeneous brain tumor entity from infancy through adulthood. ALK gene fusions enriched in congenital and infant GBM have emerged as druggable driver alterations. Understanding the molecular basis and prevalence of ALK gene rearrangements will help define GBM patients that may benefit from ALK targeted therapy.
The Water, the Air, the Marines—Camp Lejeune, Trichloroethylene, and Parkinson Disease
Authors: E. Ray Dorsey, J. Timothy Greenamyre, Allison W. Willis
Journal: JAMA Neurology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer
Authors: Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice M Walshe, Gamini S Soori, Shaker R Dakhil, James L Wade, Edward C McCarron, Sandra M Swain, Norman Wolmark
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)–based therapy. Seven-year results demonstrated a nonstatistically significant trend in disease-free survival (DFS) in favor of ELT. We present 10-year outcome results. Methods In this double-blind, phase III trial, patients with stage I-IIIA hormone receptor–positive breast cancer, disease free after 5 years of an AI or tamoxifen followed by an AI, were randomly assigned to 5 years of letrozole or placebo. Primary endpoint was DFS, defined as time from random assignment to breast cancer recurrence, second primary malignancy, or death. All statistical tests are 2-sided. Results Between September 2006 and January 2010, 3966 patients were randomly assigned (letrozole: 1983; placebo: 1983). Median follow-up time for 3923 patients included in efficacy analyses was 10.3 years. There was statistically significant improvement in DFS in favor of letrozole compared with placebo (hazard ratio [HR] = 0.85, 95% confidence interval [CI] = 0.74 to 0.96; P = .01; 10-year DFS: placebo = 72.6%, letrozole = 75.9%, absolute difference = 3.3%). There was no difference in the effect of letrozole on overall survival (HR = 0.97, 95% CI = 0.82 to 1.15; P = .74). Letrozole statistically significantly reduced breast cancer–free interval events (HR = 0.75, 95% CI = 0.62 to 0.91; P = .003; absolute difference in cumulative incidence = 2.7%) and distant recurrences (HR = 0.72, 95% CI = 0.55 to 0.92; P = .01; absolute difference = 1.8%). The rates of osteoporotic fractures and arterial thrombotic events did not differ between treatment groups. Conclusions The beneficial effect of ELT on DFS persisted at 10 years. Letrozole also improved breast cancer–free interval and distant recurrences without improving overall survival. Careful assessment of potential risks and benefits is necessary for selecting appropriate candidates for ELT.
Mitochondrial miR-23b-5p is a new biomarker of warm ischemic injury in donor livers and a candidate for graft evaluation: experimental studies
Authors: Lingxiang Kong, Yongjie Zhou, Jingsheng Yuan, Tao Lv, Jian Yang, Yujun Shi, Jiayin Yang
Journal: International Journal of Surgery (2023)

Background and aims: Warm ischemic injury (WII) stems from incorrect energy metabolism and is the main cause of graft dysfunction. Mitochondria, as the center of cellular metabolic activities, may be the key in identifying accurate indicators for evaluating the quality of grafts. Our research focuses on the screening, clinical application, and mechanism of the optimal WII mitochondrion biomarker. Approach and results: Using a 100% hepatic warm ischemia mouse model, without reperfusion, transmission electron microscopy demonstrated evident morphological changes of hepatic mitochondria at 15 min of ischemia. However, all 13 mt-mRNAs could not display continuously up-regulated consistency at 0-15-30-60 min during WII. High throughput analysis of miRNA expression in both purified mitochondria and liver tissues suggested miR-23b-5p was a potential mitochondrial microRNA (mitomiR) biomarker with high sensitivity and 0-15-30-60 min change consistency. Fluorescence in-situ hybridization and RT-qPCR further confirmed the results. Through overexpression and inhibition, the functionality of this mitomiR during WII was identified as a protective regulator in vitro and then verified in Dicer1fl/flAlbCre mice by down-regulation of other miRNAs and supplementation of mature mitomiR-23b-5p. Dual-luciferase reporter assay and the Seahorse XF analyzer determined that mitomiR-23b-5p reduced mitochondrial respiratory function by silencing mtRNR2 (16S). Clinically, mitomiR-23b-5p was positively correlated with serum ALT levels 3 days after the operation (P=0.032), and the C-statistic for 90-day graft survival rate was 0.698. Conclusion: MitomiR-23b-5p plays a protective regulatory role and implements a special mitochondrial regulation mechanism not yet reported in WII. Our clinical results further support the experimental result that the expression of MitomiR-23b-5p is closely related to the prognosis of clinical liver transplantation patients. This is a promising new biomarker for WII evaluation of donor livers.
A Smart Responsive Fluorescence‐MR Nanoprobe for Monitoring Tumor Response to Immunotherapy
Authors: Minghua Li, Junjun Tang, Chao Lin, Aijun Shen, Xiaolong Ma, Jiaqi Wu, Xiaolong Gao, Peijun Wang
Journal: Advanced Healthcare Materials (2023)

Abstract Accurately evaluating tumor responses to immunotherapy is clinically relevant. However, non‐invasive, real‐time visualization techniques to evaluate tumor immunotherapy are still lacking. Herein, a smart responsive fluorescence‐MR dual‐modal nanoprobe, QM(GP)‐MZF(CP), is reported that can be targeted for cleavage by the cytotoxic T cell activation marker granzyme B and the apoptosis‐related marker cysteine‐aspartic acid‐specific protease 3 (Caspase‐3). The probe uses quinoline‐malononitrile (QM), an aggregation‐induced emission luminogen, and Mn‐Zn ferrite magnetic nanoparticles (MZF‐MNPs), a T2‐weighted imaging (T2WI) contrast agent, as imaging molecules that are linked with the substrate peptides specific to granzyme B and Caspase‐3. Therefore, both granzyme B and Caspase‐3 can target and cleave the substrate peptides in QM(GP)‐MZF(CP). Via aggregation‐induced fluorescence imaging of QM and the aggregation‐induced T2WI‐enhanced imaging effect of MZF‐MNPs, the status of T cells after tumor immunotherapy and the subsequent triggering of tumor cell apoptosis can be determined to identify tumor responsiveness to immunotherapy and thereby evaluate the effectiveness of this therapy in the early stages of treatment.
Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?
Authors: Jeffrey A. Cohen, Anne H. Cross
Journal: JAMA Neurology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
Authors: Samuel M. Goldman, Frances M. Weaver, Kevin T. Stroupe, Lishan Cao, Beverly Gonzalez, Kalea Colletta, Ethan G. Brown, Caroline M. Tanner
Journal: JAMA Neurology (2023)

Importance An increased risk of Parkinson disease (PD) has been associated with exposure to the solvent trichloroethylene (TCE), but data are limited. Millions of people in the US and worldwide are exposed to TCE in air, food, and water. Objective To test whether the risk of PD is higher in veterans who served at Marine Corps Base Camp Lejeune, whose water supply was contaminated with TCE and other volatile organic compounds (VOCs), compared with veterans who did not serve on that base. Design, Setting, and Participants This population-based cohort study examined the risk for PD among all Marines and Navy personnel who resided at Camp Lejeune, North Carolina (contaminated water) (n = 172 128), or Camp Pendleton, California (uncontaminated water) (n = 168 361), for at least 3 months between 1975 and 1985, with follow-up from January 1, 1997, until February 17, 2021. Veterans Health Administration and Medicare databases were searched for International Classification of Diseases diagnostic codes for PD or other forms of parkinsonism and related medications and for diagnostic codes indicative of prodromal disease. Parkinson disease diagnoses were confirmed by medical record review. Exposures Water supplies at Camp Lejeune were contaminated with several VOCs. Levels were highest for TCE, with monthly median values greater than 70-fold the permissible amount. Main Outcome and Measures Risk of PD in former residents of Camp Lejeune relative to residents of Camp Pendleton. In those without PD or another form of parkinsonism, the risk of being diagnosed with features of prodromal PD were assessed individually and cumulatively using likelihood ratio tests. Results Health data were available for 158 122 veterans (46.4%). Demographic characteristics were similar between Camp Lejeune (5.3% women, 94.7% men; mean [SD] attained age of 59.64 [4.43] years; 29.7% Black, 6.0% Hispanic, 67.6% White; and 2.7% other race and ethnicity) and Camp Pendleton (3.8% women, 96.2% men; mean [SD] age, 59.80 [4.62] years; 23.4% Black, 9.4% Hispanic, 71.1% White, and 5.5% other race and ethnicity). A total of 430 veterans had PD, with 279 from Camp Lejeune (prevalence, 0.33%) and 151 from Camp Pendleton (prevalence, 0.21%). In multivariable models, Camp Lejeune veterans had a 70% higher risk of PD (odds ratio, 1.70; 95% CI, 1.39-2.07; P &amp;amp;lt; .001). No excess risk was found for other forms of neurodegenerative parkinsonism. Camp Lejeune veterans also had a significantly increased risk of prodromal PD diagnoses, including tremor, anxiety, and erectile dysfunction, and higher cumulative prodromal risk scores. Conclusions and Relevance The study’s findings suggest that the risk of PD is higher in persons exposed to TCE and other VOCs in water 4 decades ago. Millions worldwide have been and continue to be exposed to this ubiquitous environmental contaminant.
Shifting Epidemiology and Severity of Respiratory Syncytial Virus in Children During the COVID-19 Pandemic
Authors: Suchitra Rao, Isaac Armistead, Kevin Messacar, Nisha B. Alden, Emma Schmoll, Elizabeth Austin, Samuel R. Dominguez
Journal: JAMA Pediatrics (2023)

This cohort study examined changes in RSV age distribution and disease severity in Colorado children after the COVID-19 pandemic.
Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling
Authors: Saseong Lee, Eunbyeol Choi, Sehyun Chae, Jung Hee Koh, Yoolim Choi, Jung Gon Kim, Seung-Ah Yoo, Daehee Hwang, Wan-Uk Kim
Journal: Annals of the Rheumatic Diseases (2023)

'Invasive pannus' is a pathological hallmark of rheumatoid arthritis (RA). This study aimed to investigate secretome profile of synovial fibroblasts of patients with RA (RA-FLSs), a major cell type comprising the invasive pannus.Secreted proteins from RA-FLSs were first identified using liquid chromatography-tandem mass spectrometry analysis. Ultrasonography was performed for affected joints to define synovitis severity at the time of arthrocentesis. Expression levels of myosin heavy chain 9 (MYH9) in RA-FLSs and synovial tissues were determined by ELISA, western blot analysis and immunostaining. A humanised synovitis model was induced in immuno-deficient mice.We first identified 843 proteins secreted from RA-FLSs; 48.5% of the secretome was associated with pannus-driven pathologies. Parallel reaction monitoring analysis of the secretome facilitated discovery of 16 key proteins related to 'invasive pannus', including MYH9, in the synovial fluids, which represented synovial pathology based on ultrasonography and inflammatory activity in the joints. Particularly, MYH9, a key protein in actin-based cell motility, showed a strong correlation with fibroblastic activity in the transcriptome profile of RA synovia. Moreover, MYH9 expression was elevated in cultured RA-FLSs and RA synovium, and its secretion was induced by interleukin-1β, tumour necrosis factor α, toll-like receptor ligation and endoplasmic reticulum stimuli. Functional experiments demonstrated that MYH9 promoted migration and invasion of RA-FLSs in vitro and in a humanised synovitis model, which was substantially inhibited by blebbistatin, a specific MYH9 inhibitor.This study provides a comprehensive resource of the RA-FLS-derived secretome and suggests that MYH9 represents a promising target for retarding abnormal migration and invasion of RA-FLSs.
m6A modification-tuned sphingolipid metabolism regulates postnatal liver development in male mice
Authors: Shiguan Wang, Shanze Chen, Jianfeng Sun, Pan Han, Bowen Xu, Xinying Li, Youquan Zhong, Zaichao Xu, Peng Zhang, Ping Mi, Cuijuan Zhang, Lixiang Li, Haiyan Zhang, Yuchen Xia, Shiyang Li, Mathias Heikenwalder, Detian Yuan
Journal: Nature Metabolism (2023)
Mitochondrial pyruvate carrier-mediated metabolism is dispensable for the classical activation of macrophages
Authors: Linyu Ran, Song Zhang, Guosheng Wang, Pei Zhao, Jiaxing Sun, Jiaqi Zhou, Haiyun Gan, Ryounghoon Jeon, Qiang Li, Joerg Herrmann, Feilong Wang
Journal: Nature Metabolism (2023)
MnO<sub>2</sub> Coated Mesoporous PdPt Nanoprobes for Scavenging Reactive Oxygen Species and Solving Acetaminophen‐Induced Liver Injury
Authors: Yi Lu, Xinni Pan, Cheng Cao, Shanshan Fan, Haisong Tan, Shengsheng Cui, Yanlei Liu, Daxiang Cui
Journal: Advanced Healthcare Materials (2023)

As one of the most widely used drugs, acetaminophen, is the leading cause of acute liver injury. In addition, acetaminophen-induced liver injury (AILI) has a strong relationship with the overproduced reactive oxygen species, which can be effectively eliminated by nanozymes. To address these challenges, mesoporous PdPt@MnO2 nanoprobes (PPM NPs) mimicking peroxide, catalase, and superoxide dismutase-like properties are synthesized. They demonstrate nontoxicity, high colloidal stability, and exceptional reactive oxygen species (ROS)-scavenging ability. By scavenging excessive ROS, decreasing inflammatory cytokines, and inhibiting the recruitment and activation of monocyte/macrophage cells and neutrophils, the pathology mechanism of PPM NPs in AILI is confirmed. Moreover, PPM NPs' therapeutic effect and good biocompatibility may facilitate the clinical treatment of AILI.